APA

Rizzieri D. A., Feldman E., Dipersio J. F., Gabrail N., Stock W., Strair R., Rivera V. M., Albitar M., Bedrosian C. L. & Giles F. J. (20080918). A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Rizzieri David A, Feldman Eric, Dipersio John F, Gabrail Nashat, Stock Wendy, Strair Roger, Rivera Victor M, Albitar Maher, Bedrosian Camille L and Giles Francis J. 20080918. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Rizzieri D. A., Feldman E., Dipersio J. F., Gabrail N., Stock W., Strair R., Rivera V. M., Albitar M., Bedrosian C. L. and Giles F. J. (20080918). A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Rizzieri David A, Feldman Eric, Dipersio John F, Gabrail Nashat, Stock Wendy, Strair Roger, Rivera Victor M, Albitar Maher, Bedrosian Camille L and Giles Francis J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20080918.